ATE398129T1 - Reverse-turn-mimetika und diese betreffendes verfahren - Google Patents
Reverse-turn-mimetika und diese betreffendes verfahrenInfo
- Publication number
- ATE398129T1 ATE398129T1 AT02781937T AT02781937T ATE398129T1 AT E398129 T1 ATE398129 T1 AT E398129T1 AT 02781937 T AT02781937 T AT 02781937T AT 02781937 T AT02781937 T AT 02781937T AT E398129 T1 ATE398129 T1 AT E398129T1
- Authority
- AT
- Austria
- Prior art keywords
- reverse
- disease
- turn
- biologically active
- disclosed
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 230000004156 Wnt signaling pathway Effects 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 238000002399 angioplasty Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- 208000030761 polycystic kidney disease Diseases 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Structural Engineering (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Details Of Garments (AREA)
- Pinball Game Machines (AREA)
- Ceramic Products (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97647001A | 2001-10-12 | 2001-10-12 | |
| US8744302A | 2002-03-01 | 2002-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE398129T1 true ATE398129T1 (de) | 2008-07-15 |
Family
ID=26776979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02781937T ATE398129T1 (de) | 2001-10-12 | 2002-10-11 | Reverse-turn-mimetika und diese betreffendes verfahren |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1444235B1 (de) |
| JP (1) | JP4387793B2 (de) |
| KR (1) | KR100910307B1 (de) |
| CN (1) | CN100475816C (de) |
| AT (1) | ATE398129T1 (de) |
| AU (1) | AU2002348649B9 (de) |
| CA (1) | CA2462922C (de) |
| DE (1) | DE60227093D1 (de) |
| ES (1) | ES2310215T3 (de) |
| WO (1) | WO2003031448A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7576084B2 (en) | 2001-10-12 | 2009-08-18 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7671054B1 (en) | 2001-10-12 | 2010-03-02 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7566711B2 (en) | 2001-10-12 | 2009-07-28 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US8080657B2 (en) | 2001-10-12 | 2011-12-20 | Choongwae Pharma Corporation | Compounds of reverse turn mimetics and the use thereof |
| US20040072831A1 (en) * | 2001-10-12 | 2004-04-15 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7232822B2 (en) | 2001-10-12 | 2007-06-19 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| CA2537099A1 (en) * | 2003-08-28 | 2005-03-10 | Choongwae Pharma Corporation | Modulation of .beta.-catenin/tcf activated transcription |
| WO2007056593A2 (en) | 2005-11-08 | 2007-05-18 | Choongwae Pharma Corporation | α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS |
| KR100712667B1 (ko) * | 2006-04-11 | 2007-05-02 | 재단법인서울대학교산학협력재단 | 신규한 디아자 헤테로고리 유도체 및 그의 고체상 제조방법 |
| WO2007139346A1 (en) * | 2006-05-30 | 2007-12-06 | Choongwae Pharma Corporation | Composition for induction or inhibition of stem cell differentiation |
| DE102007011912A1 (de) * | 2007-03-13 | 2008-09-18 | Sanofi-Aventis | Verfahren für das Erzeugen von Peptidbibliotheken und deren Verwendung |
| JP5530427B2 (ja) * | 2008-06-06 | 2014-06-25 | 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ | アルファへリックスミメティック及び関連の方法 |
| CN102186853A (zh) | 2008-10-14 | 2011-09-14 | 株式会社棱镜生物实验室 | 治疗癌症α-螺旋模拟物 |
| CA2758904C (en) * | 2009-04-15 | 2017-04-04 | Jw Pharmaceutical Corporation | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
| EP2427451B1 (de) | 2009-05-07 | 2019-03-20 | PRISM BioLab Co., Ltd. | Alpha-helix-mimetika und damit in zusammenhang stehende methoden |
| WO2011096440A1 (ja) | 2010-02-03 | 2011-08-11 | ＰＲＩＳＭ ＢｉｏＬａｂ株式会社 | 天然変性タンパク質に結合する化合物およびそのスクリーニング方法 |
| ES2552462T3 (es) * | 2010-10-14 | 2015-11-30 | Jw Pharmaceutical Corporation | Nuevo compuesto de un mimético de giro inverso y un procedimiento de producción y uso del mismo |
| WO2012115286A1 (en) * | 2011-02-25 | 2012-08-30 | Prism Biolab Corporation | Alpha helix mimetics and methods relating thereto |
| JP6059224B2 (ja) * | 2011-08-09 | 2017-01-11 | ジェイダブリュ ファーマセウティカル コーポレーション | ピラジノ−トリアジン誘導体を含む非小細胞性肺癌の予防および治療用組成物 |
| JP6303112B2 (ja) | 2012-12-12 | 2018-04-04 | 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ | 肝線維症の予防または治療剤 |
| US9174998B2 (en) * | 2013-12-25 | 2015-11-03 | Eisai R&D Management Co., Ltd. | (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| CA2986999C (en) | 2015-06-23 | 2023-08-08 | Eisai R&D Management Co., Ltd. | Crystal of (6s,9as)-n-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2h-pyrazino[2,1-c][1,2,4]triazine-1(6h)-carboxamide |
| WO2017047762A1 (ja) * | 2015-09-18 | 2017-03-23 | 国立大学法人鳥取大学 | 低分子化合物による癌と線維化の抑制と再生促進の効果 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
| EP4051278B1 (de) | 2019-10-29 | 2025-12-17 | Eisai R&D Management Co., Ltd. | Kombination aus einem pd-1-antagonisten, einem vegfr/fgfr/ret-tyrosinkinaseinhibitor und einem cbp/beta-catenin-inhibitor zum behandeln von krebs |
| WO2022158610A1 (en) * | 2021-01-20 | 2022-07-28 | Prism BioLab Co., Ltd. | Novel bicyclic compounds |
| CN116925081A (zh) * | 2022-04-11 | 2023-10-24 | 中国科学院上海药物研究所 | 一种环肽类化合物及其应用 |
| CN117105821A (zh) * | 2023-04-18 | 2023-11-24 | 重庆普佑制药有限公司 | 一种沙库比曲中间体的制备方法 |
| WO2025174646A1 (en) * | 2024-02-12 | 2025-08-21 | Albert Einstein College Of Medicine | Inhibitors of beta-catenin c-terminal domain and methods of use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184223B1 (en) * | 1995-10-27 | 2001-02-06 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| US5929237A (en) * | 1995-10-27 | 1999-07-27 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| US6013458A (en) * | 1995-10-27 | 2000-01-11 | Molecumetics, Ltd. | Reverse-turn mimetics and methods relating thereto |
-
2002
- 2002-10-11 EP EP02781937A patent/EP1444235B1/de not_active Expired - Lifetime
- 2002-10-11 WO PCT/KR2002/001901 patent/WO2003031448A1/en not_active Ceased
- 2002-10-11 KR KR1020047005346A patent/KR100910307B1/ko not_active Expired - Fee Related
- 2002-10-11 AT AT02781937T patent/ATE398129T1/de not_active IP Right Cessation
- 2002-10-11 CA CA2462922A patent/CA2462922C/en not_active Expired - Lifetime
- 2002-10-11 CN CNB028225678A patent/CN100475816C/zh not_active Expired - Fee Related
- 2002-10-11 JP JP2003534431A patent/JP4387793B2/ja not_active Expired - Fee Related
- 2002-10-11 ES ES02781937T patent/ES2310215T3/es not_active Expired - Lifetime
- 2002-10-11 DE DE60227093T patent/DE60227093D1/de not_active Expired - Lifetime
- 2002-10-11 AU AU2002348649A patent/AU2002348649B9/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN100475816C (zh) | 2009-04-08 |
| JP4387793B2 (ja) | 2009-12-24 |
| CN1585770A (zh) | 2005-02-23 |
| EP1444235A1 (de) | 2004-08-11 |
| AU2002348649B9 (en) | 2008-06-19 |
| KR20040045504A (ko) | 2004-06-01 |
| CA2462922C (en) | 2010-05-25 |
| EP1444235B1 (de) | 2008-06-11 |
| ES2310215T3 (es) | 2009-01-01 |
| JP2005505596A (ja) | 2005-02-24 |
| CA2462922A1 (en) | 2003-04-17 |
| DE60227093D1 (de) | 2008-07-24 |
| KR100910307B1 (ko) | 2009-08-03 |
| WO2003031448A1 (en) | 2003-04-17 |
| AU2002348649B2 (en) | 2008-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE398129T1 (de) | Reverse-turn-mimetika und diese betreffendes verfahren | |
| WO2004093828A3 (en) | Reverse-turn mimetics and method relating thereto | |
| WO2005116032A3 (en) | Reverse-turn mimetics and method relating thereto | |
| ATE203025T1 (de) | Reverse-turnmimetika und damit zusammenhängendes verfahren | |
| ATE301656T1 (de) | Reverse-turnmimetika und damit zusammenhängendes verfahren | |
| WO2009051399A3 (en) | Novel compounds of reverse turn mimetics and the use thereof (1) | |
| CA2286733A1 (en) | Reverse-turn mimetics and methods relating thereto | |
| ATE474854T1 (de) | Rsv neutralisierende antikörper mit sehr hohen affinität | |
| DE60228103D1 (de) | Chemische verbindungen | |
| EA200001188A1 (ru) | ПИРРОЛО[2,3-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ | |
| WO2002050066A3 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| DK0784683T3 (da) | TIE-2-ligander, fremgangsmåder til dannelse af disse og anvendelser deraf | |
| BR0214485A (pt) | 3-cianoquinolinas como inibidores de egf-r e her2 quinases | |
| WO2006094187A3 (en) | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | |
| DK1648925T3 (da) | Bicyklisk peptid-billeddannende midler | |
| BR0109598A (pt) | Inibidores de quinase de proteìna tricìclicos | |
| DE60228098D1 (de) | Pyridin-substituierte furanderivate als raf-kinase inhibitoren | |
| ATE235551T1 (de) | Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen | |
| ATE393170T1 (de) | Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers | |
| BR0318325A (pt) | miméticos de beta-fita e método relacionado aos mesmos | |
| ATE404550T1 (de) | Chemische verbindungen | |
| DE50215004D1 (de) | Organische verbindungen mit biologischer wirkung als thrombinhemmer und ihre verwendung | |
| TH118203A (th) | ไพริมิดีนที่ถูกแทนที่ด้วยไดอะมิโน | |
| BR0209758A (pt) | Hepta-, octa- e nonapeptìdeos possuindo atividade anti-angiogênica | |
| TH62500A (th) | Nk1 แอนทาโกนิสท์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |